Effectiveness of semaglutide versus liraglutide for treating post‐metabolic and bariatric surgery weight recurrence

Objective The aim of this study was to compare the effectiveness of semaglutide versus liraglutide for treating post‐metabolic and bariatric surgery (MBS) weight recurrence. Methods A retrospective analysis of 207 adults with post‐MBS weight recurrence treated with semaglutide 1.0 mg weekly (n = 115) or liraglutide 3.0 mg daily (n = 92) at an academic center from January 1, 2015, through April 1, 2021, was conducted. The primary end point was percentage body weight change at 12 months of treatment with regimens containing semaglutide or liraglutide. Results The mean sample age was 55.2 years; mean BMI was 40.4 kg/m2; 89.9% were female; and 50% completed sleeve gastrectomy, 29% completed Roux‐en‐Y gastric bypass, and 21% completed adjustable gastric banding. Least‐squares mean weight change at 12 months was −12.92% versus −8.77% in the semaglutide and liraglutide groups, respectively (p